share_log

Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target

Benzinga ·  Jul 30 18:38  · Ratings

Needham analyst Mike Matson reiterates NeoGenomics (NASDAQ:NEO) with a Buy and maintains $19 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment